Few data exist regarding the association of plasma arginine vasopressin (AVP) and noradrenaline (NA) levels with subsequent cardiac events in acute decompensated heart failure (ADHF) patients. We measured plasma AVP and NA levels in ADHF patients on admission. In the follow-up (median: 487 days) of 291 patients, 41 cardiac events (cardiac death or re-hospitalization due to HF) were documented. The plasma AVP (26.4 versus 15.5 pg/mL, P = 0.014) and plasma NA (2347 versus 1524 pg/mL, P = 0.007) levels in the cardiac events group were significantly higher than those in the non-cardiac events group. The multivariable hazard ratios (HR) (95% confidence intervals [CI]) in the first tertile (1T) versus the third tertile (3T) of plasma AVP and NA levels were 2.97 (1.06-8.32) and 3.34 (1.21-9.26) for cardiac events, respectively. Group High (3T of combined AVP and NA) had a significantly higher incidence of cardiac events than Group Low (1T of combined groups) (HR: 3.50, 95% CI: 1.17-10.42, P = 0.017). Similarly, the relative risk ratio of cardiac events according to this stratification was more than that of plasma AVP or NA level alone (3.51, 2.65, and 2.95). Higher levels of plasma AVP and NA measured on admission may be associated with the incidence of cardiac events. Combined evaluation of these two parameters may be useful for assessing the prognosis of ADHF survivors.
T he severity of acute decompensated heart failure (ADHF) has been reported to be closely associated with the level of activation of vasoactive neurohumoral factors in patients with ADHF. 1, 2) Elevated plasma arginine vasopressin (AVP) level has been reported in patients with HF.
3) AVP can cause myocardial remodeling and exert a vasoconstrictive action mediated by V1a receptors, 4) and also induce fluid retention via V2 receptors, thereby acting as a factor increasing the preload. 5) Thus, it seems likely that AVP may have effects that can serve as aggravating factors for HF. In addition, there have been reports on the relationship of the plasma AVP levels to cardiac hypofunction in patients with acute myocardial infarction and patients with HF. 6, 7) Noradrenaline (NA) is one of the vasoactive neurohumoral factors synthesized in and released from the sympathetic nervous system (SNS). NA causes changes in hemodynamics, such as shortening of atrioventricular conduction time, increase in heart rate, increase in cardiac contractile force, and increase in peripheral vascular resistance, via the stellate ganglion. 8, 9) An increase in plasma NA levels reflects increased SNS activity in patients with heart failure. Plasma NA levels, just like plasma AVP levels, have been reported to be associated with the prognosis of cardiac events in patients with HF. 10, 11) Thus, AVP and NA are typical biomarkers that have a great bearing on the prognosis in patients with HF, both being kindred neurohumoral factors, though differing in their secretory stimulation pathways and actions in vivo. Elevation of both of these biomarkers appears to indicate an increased risk of development of cardiovascular events in the future, as compared to elevation of either biomarker alone. Several reports have dealt with the enhanced usefulness of using two or more biomarkers for appropriate stratification of the risk for future cardiac events in patients with acute HF. 12, 13) However, no previous studies have attempted to stratify the prognostic risk using a combination of plasma AVP and NA levels in patients with ADHF. Therefore, we hypothesized that the assessment of risk using the combination of plasma AVP and plasma NA levels, as compared to that of either alone, may improve the accuracy of risk Atsumi, ET AL prognosis assessment in patients with ADHF.
The purpose of this study was to investigate the association between plasma AVP and plasma NA levels at admission and the future risk of cardiac events, and furthermore, to determine whether an assessment using the combination of plasma AVP and plasma NA levels might improve the accuracy of risk assessment for cardiac events compared with that using plasma AVP or plasma NA levels alone, in patients hospitalized for ADHF and surviving to hospital discharge.
Methods

Study design and patients:
This study was designed as a prospective observational study to explore the relationship between both the plasma AVP and NA levels measured at admission and the occurrence of subsequent cardiac events in hospital survivors of ADHF, and to prepare a model for the prediction of incidence of cardiac events using a combination of these vasoactive neurohumoral factors.
The study population was drawn from 306 consecutive ADHF patients admitted to the coronary care unit at the Kawaguchi Municipal Medical Center between April 1, 2008 and March 31, 2012 for management of ADHF. Of these 306 patients, the study population consisted of 293 patients with ADHF whose blood was sampled at admission and who survived to hospital discharge. The primary endpoints of this study included cardiac events (sudden cardiac death and re-hospitalization due to worsening HF).
ADHF was diagnosed according to Framingham criteria when patients exhibited rapid onset signs and symptoms of HF resulting in unplanned hospitalization, including new onset acute HF, or decompensation of chronic HF. 14) We checked medical records to determine vital status and the cause of death. The diagnosis of sudden cardiac death was based on Braunwald's definition; 15) namely, death occurring within an hour of sudden and unexpected onset of one or more symptoms. Exclusion criteria were patients who were not expected to visit the clinic regularly or adherence to regulated treatment via medication and patients on hemodialysis. At the time of hospital admission, echocardiography was conducted to assess the left ventricular ejection fraction (LVEF) (Vivid S5, GE Healthcare, Tokyo, Japan).
All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the principles of the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all patients at inclusion. Data collection: The initial data were collected from the ADHF database and medical records of the hospital. A diagnosis of hypertension was made when the systolic pressure was >140 mmHg and/or the diastolic pressure was > 90 mmHg in stable phase, or the subject had a history of taking antihypertensive medication, or physiciandocumented history of hypertension. Diabetes was diagnosed when the fasting plasma glucose level was " 126 mg/dL and the hemoglobin A1c (HbA1c) was "6.5%, or the patient had a recent history of treatment with antidiabetic agents. A diagnosis of dyslipidemia was made when the low-density lipoprotein cholesterol level was "140 mg/dL, the triglyceride level was " 150 mg/dL, the highdensity lipoprotein cholesterol level was !40 mg/dL, or the patient was taking lipid-lowering medication. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate (eGFR) less than 60 mL/minute/ 1.73 m 2 . Smoking was defined as current smoking or smoking cessation within 1 year prior to the start of the study. Measurement of laboratory profile: Blood samples were collected at the time of presentation into tubes containing ethylenediaminetetraacetic acid and centrifuged a 3000 rpm at 4 for 15 min. The supernatants were decanted and frozen at -80 until the time of assay. The plasma AVP was measured by radioimmunoassay (SRL Co., Ltd., Tokyo, Japan). The plasma NA level was determined by high-performance liquid chromatography (SRL). The plasma level of the N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) was measured by electrochemiluminescence immunoassay (SRL). The estimated eGFR was calculated using the abbreviated MDRD (Modification of Diet in Renal Disease) equation modified by a Japanese coefficient. 16) Statistical analysis: All the statistical analyses were performed using the SPSS 12.0 software program (Statistical Package for the Social Sciences, SPSS Inc., Chicago, IL, USA). Data were expressed as the mean ± standard deviation for continuous variables and as percentages for discrete variables. Differences between the groups were analyzed by the Student's t-test and the χ 2 test for categorical variables. Data that did not have a normal distribution were expressed as medians (interquartile range), and the Mann-Whitney U test was used to evaluate the differences between the groups. In the subset analysis by tertiles of the plasma AVP and NA levels, we used analysis of variance (ANOVA) followed by Bonferroni's adjustment for covariates if differences had been detected in the patient characteristics or markers associated with ADHF.
With the objective of confirming that combined evaluation of the plasma AVP and NA levels is a valid strategy for assessing the prognostic risk for future cardiac events in patients with ADHF in the study population, receiver operating characteristic (ROC) analysis was performed and the area under the curve (AUC) was calculated for factors known to aggravate HF, including the plasma AVP and NA levels, in order to assess the accuracy of prediction of future cardiac events for each factor.
To identify independent predictors of cardiac events, multivariate Cox proportional-hazards regression analyses were performed with no adjustments (model 1), after adjustment for age and gender (model 2), and after adjustment for age, gender, and markers associated with ADHF (model 3). We then charted the survival curves using the Kaplan-Meier method between first tertile and third tertile of both plasma AVP and NA levels. Differences in survival curves were evaluated using log-rank tests. Spearman and Pearson correlation coefficients were used to assess correlations between the two continuous variables. In order to prepare a model of the risk stratification of car- Comparison of the plasma AVP and NA levels between the patient with and without cardiac events in ADHF survivors. The plasma AVP and NA levels were significantly higher in patients with cardiac events group than those in non-cardiac events group. AVP indicates arginine vasopressin; NA, noradrenaline; and ADHF, acute decompensated heart failure.
diac events, the relative risk (RR) and 95% confidence interval (95% CI) was calculated according to three classifications: 1) AVP level of the first tertile versus the third tertile; 2) NA level of the first tertile versus the third tertile; 3) Group low (L) (first tertile of combined AVP and NA levels) versus Group high (H) (third tertile of combined AVP and NA levels). P values less than 0.05 were considered to indicate statistical significance.
Results
Patients: There were 291 patients (180 male, 111 female; average age 72 ± 12 years), and the median follow-up period was 487 days [interquartile range (IQR) 130-730]. Two of 293 patients targeted for this study were not available for follow-up (follow-up rate: 99.3%). After exclusion of the above patients, the data of 291 patients were eligible for this analysis. In the ROC analysis carried out to assess the accuracy of prediction of future cardiac events for each prognostic factor in patients with HF, the AUCs for the plasma AVP and NA levels were 0.613 and 0.633, respectively, which were higher than those for other parameters. Therefore, it was confirmed that combined evaluation of the plasma AVP and NA levels is a valid tool for assessing the risk of future cardiac events in the study population (Table I) .
Comparison of patient characteristics between cardiac event group and non-cardiac event group: During the follow-up period, 41 patients developed cardiac events, of whom 38 needed to be re-admitted to the hospital due to cardiac failure, and 3 developed out-of-hospital cardiopulmonary arrest. The plasma AVP and NA levels in ADHF patients with cardiac events were significantly higher than those in ADHF patients without cardiac events (P = 0.014 and 0.007) (Figure 1 ). Age in the cardiac event group was significantly higher than that in the non-cardiac event group (P = 0.029). The proportion of female patients in the cardiac event group was significantly higher than that in the non-cardiac event group (P = 0.011). eGFR tended to be lower in the cardiac event group than that in the non-cardiac event group (P = 0.063). However, it did not reach statistical significance. Patients requiring high-dose loop diuretic administration (furosemide at !40 mg q.d.) at hospital discharge were significantly more frequent in the cardiac event group (P = 0.012). No significant differences in any other parameters of patient characteristics were noted (Table II) .
Comparison of patient characteristics according to the plasma AVP tertiles:
The body mass index and blood hemoglobin concentration decreased significantly as the plasma AVP tertile increased (P = 0.002 and 0.018). LVEF on admission decreased significantly as the plasma AVP tertile increased corresponding to an increased proportion of LVEF < 40% (both P = 0.001). There were significant differences in heart rate at hospital discharge among the tertiles of plasma AVP. No significant differences in any other factors of patient characteristics were observed among the plasma AVP tertiles (Table III) .
Atsumi, ET AL Abbreviations were as in Table I . *Median; interquartile range in parentheses. hs-CRP indicates high-sensitivity C-reactive protein; OMI, old myocardial infarction; HHD, hypertensive heart disease; VHD, valvular heart disease; ACEI, angiotensin converting enzyme inhibitor; and ARB, angiotensin II receptor blocker.
Comparison of patient characteristics according to the plasma NA tertiles: Blood hemoglobin concentration decreased significantly as the plasma NA tertile increased (P = 0.001). The presence of CKD was associated with a high plasma NA level. The serum creatinine and plasma AVP levels increased significantly as the plasma NA tertile increased (P = 0.018 and 0.001). LVEF on admission decreased significantly as the plasma NA tertile increased corresponding to both an increased proportion of LVEF < 40% (both P = 0.001) and an increase in the plasma AVP tertile increase. Patients requiring loop diuretic administration at hospital discharge were significantly more frequent as the plasma NA tertile increased (P = 0.031). There were no significant differences in any other factors of patient characteristics among plasma NA tertiles (Table IV) . Cardiac events analysis: Cox proportional-hazard regression analysis was performed to determine the associations of the tertiles of plasma AVP and NA levels with the occurrence of cardiac events in ADHF patients (Table V) . In model 1 and 3, Cox proportional-hazard regression analysis models identified at-admission plasma AVP and NA levels in the third tertile as compared to those in the first ASSOCIATION BETWEEN AVP AND NA WITH ADHF Tables I and II . *Median; interquartile range in parentheses. ANOVA and post hoc tests with Bonferroni correction were performed to test between-group differences. † P < 0.05, ‡ P < 0.01, § P < 0.001, # P < 0.0001 versus 1T. † † P < 0.05, ‡ ‡ P < 0.01, § § P < 0.001, ## P < 0.0001 versus 2T.
tertile as being independently predictive of cardiac events in ADHF patients. However, in model 3, like in models 1 and 2, at-admission plasma AVP and plasma NA levels in the third tertile were identified as independent poor prognostic factors as compared to those in the first tertile, and in both models using at-admission plasma AVP and plasma NA levels as independent variables, the results suggested that the prescription of furosemide !40 mg/ day at discharge was an independent predictor of cardiac events, and that a higher Hb level at admission was an independent predictor of the absence of cardiac events, i.e., the lower the Hb level, the higher the incidence of cardiac events. Kaplan-Meier survival analysis comparing the first tertile of plasma AVP and NA levels to the third tertile for cardiac events was significant for log-rank analysis (Figure 2) . Cardiac risk assessment using the combination of plasma AVP and NA levels: We evaluated the risk stratification of cardiac events in the long-term prognosis in ADHF patients according to combination of plasma AVP level and plasma NA level. A positive relation between the plasma AVP and NA levels was found (Figure 3 ). Accordingly, a Kaplan-Meier statistical analysis was performed to analyze the risk of cardiac events between the low-risk group and the high-risk group (Figure 4) . The low-risk group, Group L (n = 60), consisted of patients in the first tertile of the correlated plasma AVP and plasma NA levels. The high-risk group, Group H (n = 65), consisted of patients in the third tertile of the correlated plasma AVP and plasma NA levels. Group H had a significantly higher incidence of cardiac events than Group L, and HR according to this stratification was revealed to be higher than HR as calculated in tertiles of plasma AVP level or plasma NA level alone.
The rates of cardiac events in the plasma AVP 3T and plasma NA 3T subgroups were 18.8% (18/96 pa-Atsumi, ET AL Tables I and II . *Median; interquartile range in parentheses. ANOVA and post hoc tests with Bonferroni correction were performed to test between-group differences. † P < 0.05, ‡ P < 0.01, § P < 0.001, # P < 0.0001 versus 1T. † † P < 0.05, ‡ ‡ P < 0.01, § § P < 0.001, ## P < 0.0001 versus 2T.
tients) and 21.4% (21/98 patients), respectively. In Group H, the rate was 24.6% (16/65 patients). The relative risk between Group H and Group L with increased levels (in the 3T) of both plasma AVP and plasma NA was higher by 32% as compared to that calculated based on elevation of the plasma AVP level alone and by 19% as compared to that calculated based on elevated plasma NA level alone, indicating the likelihood that use of the combined plasma AVP and plasma NA data enhance the accuracy of the risk stratification for future cardiac events in ADHF patients ( Figure 5 ).
Discussion
The main findings of this study were as follows: Plasma AVP and NA, which are neurohumoral factors whose levels increase during exacerbation of HF, were associated with similar hemodynamic changes. The hazard ratios and relative risk in the high plasma AVP and NA level group (consisting of the third tertile of both plasma AVP and plasma NA) versus the low plasma AVP and NA level group (consisting of the first tertile of both plasma AVP and plasma NA) were higher than those calculated using the plasma AVP or plasma NA levels alone. Namely, our results suggested that assessment using the combination of plasma AVP and NA levels may improve the accuracy of the prognostic risk assessment as compared to that using plasma AVP or plasma NA levels alone in ADHF survivors.
It is considered a rational phenomenon that combined evaluation of a plurality of biomarkers pertinent to the prognosis in patients with HF provides improved predictive power for future occurrence of cardiovascular events as compared to evaluation based on a single biomarker. In Kaplan-Meier curves comparing cardiac events according to plasma AVP levels (A) and NA levels (B) in ADHF survivors during follow-up period. Cardiac events rate was significantly higher in the third tertile groups of plasma AVP level and NA level than those in the first tertile groups. AVP indicates arginine vasopressin; NA, noradrenaline; and ADHF, acute decompensated heart failure.
Atsumi, ET AL Correlation between plasma AVP level and plasma NA level in ADHF survivors. Although a positive relation between the plasma AVP and NA levels was found, a normal distribution pattern was not established. However, the normal distribution pattern which was established in an analysis of correlated log AVP and log NA enabled us to identify high and low-risk groups. AVP indicates arginine vasopressin; NA, noradrenaline; and ADHF, acute decompensated heart failure. The Group H had a significantly higher incidence of cardiac events than the Group L. ADHF indicates acute decompensated heart failure; H, higher; and L, lower.
particular, risk stratification of the prognosis in patients with HF based on a combination of different neurohumoral factors may be useful for devising appropriate treatment strategies for preventing exacerbations of HF. The present study is the first report that attempts to stratify the prognostic risk of ADHF patients using a combination of the plasma AVP and NA levels, both of which are known as determinants of the prognosis in ADHF patients. The study is expected to afford a foundation for future prognosis prediction in patients with HF. Many basic and clinical studies have reported that treatments for HF improve cardiac hypofunction through suppression of the activities of vasoactive neurohumoral factors such as AVP and NA. 17) Considering the importance of LVEF as a prognostic factor in patients with ADHF, 18) both an insufficient reduction of plasma AVP and NA levels and insufficient improvement of LVEF may be involved in the occurrence of cardiac events. However, there was no statistically significant difference in the LVEF between the cardiac event and the no-cardiac event groups, because the patients in present study included both HF patients with preserved LVEF and those with reduced LVEF. In the present study, the results of analysis using Cox proportional-hazards regression model 3 suggested that high plasma AVP and plasma NA levels at admission, high-dose requirement of diuretics at discharge, and low Hb levels at admission are poor prognostic factors in patients with ADHF. Previous large-scale clinical studies have reported that both anemia 19) and administration of high-dose diuretics at discharge 20) aggravate the prognosis in patients with HF, consistent with the results of the present study.
This study confirmed that an increase of plasma NA levels, resulting from activation of sympathetic nervous activity, such as renin-angiotensin-aldosterone system (RAAS) activation, is an independent predictor in the long-term prognosis in ADHF patients. This may support many lines of evidence suggesting that, similar to RAAS inhibitors, β-blockers, which suppress the increase of NA secretion, improve the long-term prognosis in ADHF patients, although this is a paradoxical inference. 2, 21) It has been reported that in patients with ADHF, the severity of HF is also correlated with plasma AVP levels. 22, 23) Consistent with the findings of our study, it was recently reported that in the long-term prognosis of ADHF patients with high plasma levels of AVP or C-terminal preprovasopressin, copeptin level is poor. 24) It is noteworthy that tolvaptan, a vasopressin V2 receptor antagonist that suppresses the effect of AVP, has been reported to improve symptoms in patients with HF in the short-term. [25] [26] [27] [28] This may be evidence supporting our results that the prognosis of patients with higher plasma AVP levels is poorer and that the suppression of AVP activity may lead to the improvement of the pathophysiological condition in patients with ADHF. More detailed analysis of the physiological activities of AVP and the pathogenesis of HF may expand the spectrum of available treatment options for ADHF. This will continue to be a topic for investigation. We expect that our study results will serve as a foundation for future research.
Evidence has been established to suggest that the development of HF can be improved by suppressing the activation of the SNA and RAAS, and also by suppressing the increase in plasma AVP levels due to the sudden failure of cardiovascular hemodynamics, in ADHF patients. With the aim of further improving the prognosis of patients with HF, treatment guidelines may be established based on the factors examined in this study. Study limitations and Clinical implications: First, we did not investigate the relationship of plasma AVP and plasma NA levels at hospital discharge or other important prognostic factors in heart failure. Second, it is difficult to rule out the possibility that drugs used before the patients' admission for ADHF may have affected the plasma AVP and plasma NA levels. Finally, it is difficult to rule out the possible existence of bias in patient selection and treatment because this study was conducted at a single in-stitution with a limited number of patients. In the future, large-scale multicenter studies or drug intervention studies are required to test the validity of these results. This study attempts to show that the analysis of AVP and NA levels combined is a more accurate predictor for the risk assessment of cardiac events in patients with ADHF than the analysis of either AVP or NA level alone. While the results of this study confirmed this hypothesis, further studies are needed to provide stronger supportive evidence.
Furthermore, this study concluded, as follows, that combined evaluation of the plasma AVP and NA levels is a valid tool for prognosis prediction in patients with HF (ROC analysis also confirmed the validity of this combined evaluation in the study population): although AVP and NA have different metabolic pathways in vivo, both are neurohumoral factors that are closely involved in the development of ADHF and exert strong effects on the cardiovascular system. However, a number of prognostic factors have been reported in patients with ADHF, which act through very complex networks and different metabolic pathways. Further studies are required in the future to assess whether the combination of biomarkers examined in this study is optimal.
Conclusion
The results of this study showed that plasma AVP and NA levels, which increase during ADHF, are independent predictors of the future risk of the occurrence of cardiac events in patients surviving to hospital discharge. Furthermore, use of the combination of plasma AVP and NA levels, as compared to that of either alone, may improve the accuracy of risk assessment for cardiac events in patients with ADHF. However, further studies are needed to confirm these findings.
